China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate
This article was originally published in PharmAsia News
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
You may also be interested in...
A lack of a reporting mechanism for minor or moderate changes to approved pharmaceuticals in China makes it difficult for pharmaceutical manufacturers to make lifecycle improvements to products marketed there. Long review timelines and unclear expectations during inspections further complicate the picture.
Only 60% of sterile drug manufacturers passed the new GMP standard in China, as smaller companies chose to quit the market.
In a sign of increasing confidence by Chinese regulators, CFDA banned an injectable antibiotic from Daewoong Pharmaceutical after the company rejected an overseas inspection request due to ongoing upgrades at a Korean plant.